Tagged Articles

Bydureon 33 articles

Weekly, daily versions of diabetes drugs have similar risk-benefit profile

Once-weekly versions of a popular class of type 2 diabetes drugs carry a similar risk-benefit profile as daily-dose versions of drugs in the same class, a new study has found. The study involved type 2 diabetes drugs known as glucagon-like peptide-1 receptor agonists, or GLP1 agonists. The drugs are designed to improve blood sugar control, but also carry the attractive side effect of weight loss. Obesity and being overweight are risk factors for type 2 diabetes. All are administered by injection. GLP1 agonists include the brand names Byetta (exenatide) and Victoza (liraglutide), which are administered once or twice daily; and ... Read More

Novo Nordisk could reap billions from experimental diabetes pill

Drug maker Novo Nordisk has enjoyed booming profits from its injectable diabetes treatment Victoza, thanks to winning approval for a potent version of the drug, marketed as Saxenda, as an obesity treatment. But it’s new oral version of a diabetes drug from the same class as Victoza could send profits as high as $20 billion per year. In the pharmaceutical industry, drugs that reap annual profits of at least $1 billion are called blockbusters. There is a special term for a drug that exceeds $10 billion in sales – super-blockbuster, says Seeking Alpha. These drugs are few and far between, ... Read More

Novo Nordisk tests new type 2 diabetes treatment

Drug maker Novo Nordisk’s experimental, once-weekly type 2 diabetes treatment semaglutide is effective at lowering blood sugar levels and triggering weight loss in phase III study participants. However, the drug did have a higher dropout rate – 5 to 6 percent – due to side effects. Semaglutide is a GLP-1 analogue, which is the same class as the diabetes treatments Byetta, Bydureon, and Victoza, the latter of which is also made by Novo Nordisk. Like Byetta, Bydureon and Victoza, semaglutide is administered by injection. Novo Nordisk also has an oral version of semaglutide, which is currently in phase II clinical ... Read More

Four Dangerous Diabetes Drugs

Type 2 diabetes is a growing epidemic around the world with an estimated one in 10 adults predicted to be suffering from the disease by 2030, according to the International Diabetes Foundation. Diabetes increases the risk for serious health complications including heart disease, kidney disease, cancer, blindness, dementia and amputations from neuropathy. Many diabetics require medication to help control blood sugar levels. There are dozens of diabetes treatments on the market and more being developed. But these drugs come at a risk. Here are five type 2 diabetes drugs that carry dangerous side effects: Invokana/Invokamet – Known chemically as canagliflozin, Invokana ... Read More

Substantial growth expected in type 2 diabetes treatment market

The global market for type 2 diabetes treatments is expected to increase in value over the next few years from a value of $23.5 billion in 2014 to an estimated $39 billion by 2021, fueled by the increasing number of people developing the disease and the barrage of new brand-name diabetes treatments entering the market. The prediction was made by business intelligence provider GBI Research, which published the report Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2012 – Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth. The company said the increase will occur across the ... Read More

Type 2 diabetes drugs and pancreatic cancer

A class of type 2 diabetes medications may help fight prostate and pancreatic cancers, while another class of diabetes drugs may increase a patient’s risk of developing the deadly diseases. Cancer cells require a high amount of glucose in order to thrive. Research at the University of California-Los Angeles has found that diabetes drugs known as sodium-dependent glucose transporters, or SGLTs, could be used to block a substance in the body that feeds and promotes the growth of pancreatic and prostate cancer cells. This, they say, may offer promise in the treating of these cancers and ideally prolonging patient survival. ... Read More

Drugmaker scraps transdermal patch treatment for diabetes

Novo Nordisk is severing ties with Johnson & Johnson spinoff Zosana Pharma in the development of a microneedle patch system for its Type 2 diabetes treatment semaglutide. The companies had reported “continued progress” during development of the drug delivery system and Novo Nordisk would give no reason for ending the partnership. However, Novo Nordisk recently reported trial success of an oral formulation of a similar type 2 diabetes treatment and could be focusing its energies there. Semaglutide is a GLP-1 analogue which shares a class with the diabetes treatments Byetta, Bydureon and Victoza. These drugs are generally administered by injection. ... Read More

Novo Nordisk becomes top diabetes drug seller with Victoza

Danish drug company Novo Nordisk has become the top seller of diabetes medications thanks to its blockbuster type 2 diabetes treatment Victoza (liraglutide), which brought in a whopping $2 billion in sales, up 15 percent over last year. Novo Nordisk displaced Sanofi, which sells numerous insulin products including Lantus, insulin-delivery devices as well as the diabetes drugs Lyxumia (lixisenatide) and Amaryl/Amarel (glimepiride). Victoza was approved by the Food and Drug Administration (FDA) in 2010 and became one of the newer members of a new class of diabetes medications known as incretin mimetics. Other drugs in this class include Byetta/Bydureon (exenatide) ... Read More

Diabetes drugs may help reduce craving, but patients risk side effects

A class of type 2 diabetes drugs appear to change the brain’s response to food, leading to weight loss, and could also help people fight cravings for drugs, alcohol and nicotine as well, researchers suggest. The class of drugs, known as GLP-1 receptor agonists, or GLP-1 drugs, are known by the brand name diabetes treatments Bydureon, Byetta and Victoza. Since weight gain is already a contributing factor to the development of type 2 diabetes, the weight loss side effect offered by GLP-1 drugs is attractive. Late last year, Novo Nordisk received FDA approval for Saxenda, a high-dose version of its ... Read More

Weight loss from newer diabetes drugs may come at steep price

Newer classes of type 2 diabetes drugs can help patients lose weight, but that benefit may come at a high price. Being overweight is a risk factor for type 2 diabetes. Patients diagnosed with the chronic disease are generally advised to adopt a healthy diet and get regular exercise to help keep their blood sugar levels in check. Uncontrolled diabetes can increase the risk of serious health problems including heart disease, kidney disease, some cancers, blindness, neuropathy, and dementia. Losing weight through diet and exercise can help diabetics better manage and, in some cases, fend off the disease. However, reaching ... Read More